1. Academic Validation
  2. Evaluation of PAX1/ ST6GALNAC5 methylation as a triage test for cervical intraepithelial neoplasia and cervical cancer

Evaluation of PAX1/ ST6GALNAC5 methylation as a triage test for cervical intraepithelial neoplasia and cervical cancer

  • Epigenomics. 2023 Feb;15(3):131-145. doi: 10.2217/epi-2022-0396.
Yu Wang 1 2 Jun Chuan 2 Biyin Zhu 2 Yuee Zu 3 Rong Zhang 4 Lin Tang 2 Yongchun Wen 3 Ting Yang 2 Kexin Chen 2 Xiang Chen 2 Zhongxin Bu 2 Sundandan Zhuan 2 Zhanping Zhao 2 Qing He 2 Wei Li 1 Jun He 3
Affiliations

Affiliations

  • 1 School of Life Sciences & Technology, Tongji University, Shanghai, 200092, China.
  • 2 GeneTalks Biotech Co., Ltd, Changsha, Hunan, 410000, China.
  • 3 Changsha Hospital for Maternal & Child Health Care, Changsha, Hunan, 41000, China.
  • 4 Department of obstetrics and gynecology, The Second Affiliated Hospital of Soochow University, Suzhou, Nanjing, 215008, China.
Abstract

Aim: To identify DNA methylation markers for triage in a cohort of human papillomavirus-positive (HPV+) women. Methods: The methylation markers were identified and evaluated for the detection of cervical high-grade squamous intraepithelial lesions (HSILs) or cervical Cancer (collectively referred to as 'HSIL+') in HPV+ women (n = 692). Results: Combined PAX1/ST6GALNAC5 methylation testing yielded HSIL+ sensitivity of 0.838 and 0.818, with a specificity of 0.827 and 0.810, in the training and test sets, respectively. For cervical Cancer, the specificity and sensitivity were 0.969 and 1.000 in the training set and 0.967 and 0.875 in the test set. Moreover, the combined marker methylation test (0.86; 77/90) was more sensitive than the cytology (0.31; 28/90) for HSIL+. Conclusion: The combined PAX1/ST6GALNAC5 marker may have clinical application for detecting HSIL+ in HPV+ women undergoing screening.

Keywords

HPV screening; cervical intraepithelial neoplasia; clinical performance; cytology; diagnostic accuracy; epigenetic; squamous intraepithelial lesion.

Figures
Products